Clinical Data to Get $1.5M from Sale of Non-core Assets | GenomeWeb

NEW YORK (GenomeWeb News) – Clinical Data today said that it would receive $1.5 million from the sale of substantially all of the property and equipment at Avalon Pharmaceuticals' Germantown, Md., facility.

The Newton, Mass.-based drug and pharmacogenomic assay developer acquired Avalon earlier this year for $10 million, providing Clinical Data with a pipeline of oncology biomarkers and a biomarker discovery platform that will be used to identify diagnostic and therapeutic candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.